AcadeMedia AB (publ) (ACAD) Q1 Sales Up 14.1%, Adj. EBITA SEK 215M

AcadeMedia AB (publ) reported Q1 net sales of SEK 4,679M, up 14.1% YoY, with organic growth of 4.8%. Adjusted EBITA was SEK 215M, up from SEK 182M a year earlier, with a margin of 4.6% vs 4.4%.

Original reporting
Published Nov 2, 2026, 6:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 6:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AcadeMedia AB (publ) (ACAD) Q1 Sales Up 14.1%, Adj. EBITA SEK 215M — source image
Decision brief

The 30-second read

$ACADBullishLow
01

Why it matters

The earnings beat suggests the company is executing its growth strategy, potentially prompting short‑term buying interest.

02

Market read

First‑report earnings data with notable sales and margin improvement; modest but actionable for regional investors.

03

What to watch

Currency fluctuations and potential regulatory changes in education funding could affect future results.

Relevance 6/10Novelty 6/10Timing: post‑market today

Background

AcadeMedia AB is a leading provider of education services in the Nordic region, listed on Nasdaq Stockholm.

Company-level read

Ticker impact

$ACADBullishMedium confidence
Context

Q1 net sales rose 14.1% YoY to SEK 4,679M and adjusted EBITA increased to SEK 215M, indicating stronger revenue and margin growth.

Expected impact

likely upward pressure as the market prices in the better‑than‑expected sales and margin expansion

Evidence & confidence

First‑report earnings numbers show solid top‑line growth and margin improvement, which typically support a short‑term rally.

Market effects

Swedish education services sector may see renewed interest as the company demonstrates growth potential.

Nordic markets could see modest positive bias from the earnings beat.

Limited; primarily relevant to investors focused on European education stocks.

Counterpoint

Growth may be unsustainable if organic expansion slows; valuation could be stretched.

Key entities

  • AcadeMedia AB

    Swedish education services provider reporting Q1 results.

Related articles

$ACADHighAI 8/10

Acadia Pharma (ACAD) Q3 2026 Earnings Call Transcript

Acadia Pharma (ACAD) reported Q3 2026 total revenues of $342M, up 22% YoY. DAYBUE sales reached $140M, up 39% YoY, leading to raised 2026 guidance. NUPLAZID sales grew 12% YoY to $202M. The company extended DAYBUE patent protection to 2041 and plans a 2027 regulatory submission in Japan. Pipeline updates include remlifanserin and ACP-211, with peak sales potential of $11B.

$ACADHighAI 8/10

RBC raises Acadia Pharmaceuticals stock price target on Daybue growth

RBC Capital raised its price target for Acadia Pharmaceuticals (ACAD) to $38, citing strong Daybue uptake and growth potential. The firm expects European launch and pipeline readouts to drive future sales. Acadia reported Q3 2026 earnings of $0.31 per share, beating estimates, with revenue of $342 million. Daybue sales grew 39% YoY to $140 million, while Nuplazid sales increased 12% to $202 million. The company narrowed its 2026 revenue guidance to $1.265B-$1.295B.

$ACADMed

ACADIA Pharmaceuticals Inc (ACAD) Q3 2026 Earnings Call Highlights: Record Debut Sales

ACADIA Pharmaceuticals (ACAD) reported Q3 2026 earnings, with record Debut sales but mixed drug trial results. The RADIANT study missed significance, and the 30 mg dose of remlifanserin is discontinued. NewPlazid sales guidance was narrowed, and SG&A expenses rose. Litigation risks remain, with a patent appeal pending. Management discussed optimization plans and long-term strategies for key drugs.